Longitudinal analysis of participants in the KEEP Mexico's chronic kidney disease screening program

Archives of Medical Research

Volumn 44, Issue 8, 2013, Pages 650-654

  Obrador, Gregorio T ^a   Villa, Antonio R ^a   Olvera, Nadia ^b   Gutiérrez, Verónica ^b   Contreras, Daniela ^a   Reyes, Rebeca ^b  

^a UNIVERSIDAD PANAMERICANA   (Mexico)

^b Mexican Kidney Foundation   (Mexico)

Author keywords

Chronic kidney disease; Diagnosis; Screening

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEXICO; OBESITY; PREVALENCE; RANDOM SAMPLE; SCREENING;

CHRONIC KIDNEY DISEASE; DIAGNOSIS; SCREENING;

ADULT; DIABETES MELLITUS; EARLY DIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; INCIDENCE; KIDNEY FAILURE, CHRONIC; LONGITUDINAL STUDIES; MALE; MASS SCREENING; MEXICO; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84889588280     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2013.10.006     Document Type: Article

References (11)

1. Obrador G.T., Garcia-Garcia G., Villa A.R., et al. Prevalence of chronic kidney disease in the Kidney Early Evaluation Program (KEEP) Mexico and comparison with KEEP US. Kidney Int 2010, 77:S2-S8.
2. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39(suppl 1):S46-S75. National Kidney Foundation.
3. Levey A.S., Eckardt K.U., Tsukamoto Y., et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005, 67:2089-2100.
4. Obrador G.T., Mahdavi-Mazdeh M., Collins A.J. Establishing the Global Kidney Disease Prevention Network (KDPN): A Position Statement from the National Kidney Foundation. Am J Kidney Dis 2011, 57:361-370.
5. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
6. Parving H.-H., Lehnert H., Brachner-Mortensen J., et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870-878.
7. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
8. Jafar T.H., Stark P.C., Schmid C.H., et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003, 139:244-252.
9. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007, 49:S12-S154.
10. American Diabetes Association. Standards of Medical Care in Diabetes-2011. Diabetes Care 2011, 34:S11-S61.
11. Vassalotti JA, Collins AJ, Suying L, etal., and Kidney Early Evaluation Program investigators. Longitudinal analysis of a U.S. population at risk for chronic kidney disease. Abstract presented at the 2009 Annual Meeting of the American Society of Nephrology.